Literature DB >> 23449427

Nitroso-redox imbalance affects cardiac structure and function.

Vasileios Karantalis, Ivonne Hernandez Schulman, Joshua M Hare.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23449427      PMCID： PMC4052892          DOI： 10.1016/j.jacc.2012.12.016

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  40 in total

Review 1.  Surrogate markers for cardiovascular disease: structural markers.

Authors:  G B John Mancini; Björn Dahlöf; Javier Díez
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

2.  Nitroso-redox balance in the cardiovascular system.

Authors:  Joshua M Hare
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

3.  Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium.

Authors:  Roberto M Saraiva; Khalid M Minhas; Shubha V Y Raju; Lili A Barouch; Eleanor Pitz; Karl H Schuleri; Koenraad Vandegaer; Dechun Li; Joshua M Hare
Journal:  Circulation       Date:  2005-11-21       Impact factor: 29.690

4.  nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction.

Authors:  Dana Dawson; Craig A Lygate; Mei-Hua Zhang; Karen Hulbert; Stefan Neubauer; Barbara Casadei
Journal:  Circulation       Date:  2005-12-13       Impact factor: 29.690

5.  Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy.

Authors:  Khalid M Minhas; Roberto M Saraiva; Karl H Schuleri; Stephanie Lehrke; Meizi Zheng; Anastasios P Saliaris; Cristine E Berry; Lili A Barouch; Konrad M Vandegaer; Dechun Li; Joshua M Hare
Journal:  Circ Res       Date:  2005-12-15       Impact factor: 17.367

6.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

7.  A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase.

Authors:  Shintaro Kinugawa; Harer Huang; Ziping Wang; Pawel M Kaminski; Michael S Wolin; Thomas H Hintze
Journal:  Circ Res       Date:  2005-01-06       Impact factor: 17.367

8.  Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus.

Authors:  S Lehto; L Niskanen; T Rönnemaa; M Laakso
Journal:  Stroke       Date:  1998-03       Impact factor: 7.914

9.  Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling.

Authors:  Shakil A Khan; Kwangho Lee; Khalid M Minhas; Daniel R Gonzalez; Shubha V Y Raju; Ankit D Tejani; Dechun Li; Dan E Berkowitz; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-14       Impact factor: 11.205

10.  Increased neuronal nitric oxide synthase-derived NO production in the failing human heart.

Authors:  Thibaud Damy; Philippe Ratajczak; Ajay M Shah; Emmanuel Camors; Isabelle Marty; Gerd Hasenfuss; Françoise Marotte; Jane-Lise Samuel; Christophe Heymes
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321
View more
  9 in total

1.  Clinical research skills development program in cell-based regenerative medicine.

Authors:  Ivonne Hernandez Schulman; Viky Suncion; Vasileios Karantalis; Wayne Balkan; Joshua M Hare
Journal:  Stem Cells Transl Med       Date:  2014-12-29       Impact factor: 6.940

2.  β3-Adrenoceptor, glutathionylation, and diabetic cardiomyopathy. Focus on "β3-Adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade".

Authors:  Stephen M Black
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-15       Impact factor: 4.249

3.  Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Authors:  Michael M Givertz; Kevin J Anstrom; Margaret M Redfield; Anita Deswal; Haissam Haddad; Javed Butler; W H Wilson Tang; Mark E Dunlap; Martin M LeWinter; Douglas L Mann; G Michael Felker; Christopher M O'Connor; Steven R Goldsmith; Elizabeth O Ofili; Mitchell T Saltzberg; Kenneth B Margulies; Thomas P Cappola; Marvin A Konstam; Marc J Semigran; Steven E McNulty; Kerry L Lee; Monica R Shah; Adrian F Hernandez
Journal:  Circulation       Date:  2015-04-14       Impact factor: 29.690

4.  Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.

Authors:  Michael M Givertz; Douglas L Mann; Kerry L Lee; Jenny C Ibarra; Eric J Velazquez; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  Circ Heart Fail       Date:  2013-07       Impact factor: 8.790

Review 5.  Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase.

Authors:  Sailay Siddiqi; Mark A Sussman
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-08

6.  Molecular Signature of Nitroso-Redox Balance in Idiopathic Dilated Cardiomyopathies.

Authors:  Sara Menazza; Angel Aponte; Junhui Sun; Marjan Gucek; Charles Steenbergen; Elizabeth Murphy
Journal:  J Am Heart Assoc       Date:  2015-09-22       Impact factor: 5.501

7.  microRNA-206 is involved in survival of hypoxia preconditioned mesenchymal stem cells through targeting Pim-1 kinase.

Authors:  You Zhang; Wei Lei; Weiya Yan; Xizhe Li; Xiaolin Wang; Zhenao Zhao; Jie Hui; Zhenya Shen; Junjie Yang
Journal:  Stem Cell Res Ther       Date:  2016-04-22       Impact factor: 6.832

Review 8.  Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.

Authors:  Ke Si; Chijing Wei; Lili Xu; Yue Zhou; Wenshan Lv; Bingzi Dong; Zhongchao Wang; Yajing Huang; Yangang Wang; Ying Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-12       Impact factor: 5.555

Review 9.  Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding.

Authors:  Steven J Simmonds; Ilona Cuijpers; Stephane Heymans; Elizabeth A V Jones
Journal:  Cells       Date:  2020-01-18       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.